The “complementation” strategy allowed characterization of both SCD1 as well as the specificity of various fatty-acid synthesis inhibitors, and clarifies the mechanism by which SCD1 inhibition restricts cancer cell proliferation. This evidence concerns the gene SCD and cancer.